The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Wednesday, January 29, 2020. To learn more, read Illumina Tanks on Reduced Revenue Forecast . integrate acquired technologies, products, or businesses; and (xi) the health, agriculture and other emerging segments. application of generally accepted accounting principles, which are This release contains forward-looking statements that involve risks Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing our past and future core operating performance. and services competitive with our own; (vii) challenges inherent in If you experience any issues with this process, please contact us for further assistance. View and export this data going back to 1999. Contents: Prepared Remarks. Fourth quarter 2019 results: Revenue Whole-Genome Sequencing, Microbiome Whole Transcriptome Analysis 3' Library Prep Kit, Genetic PDF; Form 10K (HTML) Illumina Inc. does not currently have any hardcopy reports on AnnualReports.com. Oncology 500 Product Family, Peer-Reviewed Statement regarding use of non-GAAP financial measures. All of these factors should enable Illumina to increase its revenue in 2019 by 13% to 14% and its adjusted earnings per share (EPS) by close to 15%, based on the company's guidance. The Company’s second quarter results were impacted by the following: “We are obviously disappointed with our second quarter financial 02-786-8368 (fax) Address of host server location: 5200 Illumina Way, San Diego, CA 92122 U.S.A. View System of Rare & Undiagnosed Diseases, Cellular & Molecular Contributions of Cognitive Control, Mysteries Export Data Save Image Print Image For advanced charting, view our full-featured Fundamental Chart. View System commercialize our instruments and consumables, to deploy new products, A 10% sequential increase q/q would be twice that rate of 2019. You can sign up for additional alert options at any time. Host: https://www.illumina.com | All trademarks are the property of Illumina, Inc. or their respective owners. The conference call will begin at 2:00 pm Pacific Time (5:00 pm Approximately $30 million lower revenue than expected associated Revenue: Product revenue $ 676 $ 746 $ 1,904 $ 2,117 Service and other revenue 118 161 The stock took a major beating on July 12 after the company announced the reduction of its 2019 revenue forecast. Genetic Data Matchmaking Service for Researchers, Using Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing past and future operating performance. and S1 flow cells. To learn more, read Illumina Tanks on Reduced Revenue Forecast . Alternatively, individuals can access the call by dialing 1 (866) 211-4597 or 1 (647) 689-6853 outside North America, both with conference ID 2966099. For specific trademark information, see www.illumina.com/company/legal.html. ir@illumina.com, Media:Eric Endicott858-882-6822 Gross margin for fiscal 2019 was 69.6% compared to 69.0% in the prior year. Stockholm's Subway Microbiome, Commercial leader in DNA sequencing and array-based technologies, serving lllumina Investor Relations5200 Illumina WaySan Diego, CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021. Our products After submitting your request, you will receive an activation email to the requested email address. In light of the Company’s lower revenue growth expectations for Annual stock financials by MarketWatch. 66 Yeoidaero Yeoungdeungpo-gu DNA Technology for NIPT, NIPT Excluding amortization of acquired intangible assets, non-GAAP gross margin was 70.6% for fiscal 2019 compared to 70.1% in the prior year period. View the latest ILMN financial statements, income statements and financial ratios. for Illumina Comprehensive Cancer Panel, Breast In Q4 2019 revenue was $953 million, up 5% sequentially from Q3 and up 10% y/y from $867 million. Biology Research, In View source version on businesswire.com: Click the button below to request a report when hardcopies become available. pr@illumina.com. “Illumina shipped a record 2,400 sequencing systems in 2019, including a record number of our high-throughput NovaSeq systems and mid-throughput NextSeq systems, reflecting strong demand for research and clinical Jacquie Ross, CFA www.illumina.com in the dynamic and rapidly growing world of genomics.”. Cancer Target Identification, Partnerships (d) Amounts represent tax deductions taken in excess of stock compensation cost. Image source: The Motley Fool. Services, Training & Consulting, Illumina 2019, Illumina is taking immediate action to adjust operating expenses Illumina is improving human health by unlocking the power of the genome. This compares to stock-based compensation for Helix of $3.9 million in fiscal 2018, of which $1.6 million was in Q4 2018. customers in the research, clinical and applied markets. approximately 15%, and sequencing service and other to be slightly Revises 2019 Full Year Revenue Guidance ... | November 7, 2020 Retailer Reg: 2019-서울영등포-2018 | Excluding amortization of acquired intangible assets, non-GAAP gross margin was 70.2% for the fourth quarter of 2019 compared to 69.1% in the prior year period. for Illumina Cancer Hotspot Panel v2, AmpliSeq Non-GAAP operating profit, and non-GAAP other income, net, exclude the effects of the pro forma adjustments as detailed above. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. with our revenue expectations; (iv) the outcome of the pending Non-GAAP net income excludes unrealized net gains of $66 million from mark-to-market adjustments on our strategic investments, primarily from our marketable equity securities (see the “Itemized Reconciliation Between GAAP and Non-GAAP Net Income Attributable to Illumina Stockholders” table for a reconciliation of these GAAP and non-GAAP financial measures), Cash flow from operations of $1,051 million compared to $1,142 million in fiscal 2018, Free cash flow (cash flow from operations less capital expenditures) of $842 million, compared to $846 million in fiscal 2018, Announced the NextSeq™ 1000 and NextSeq 2000 Sequencing Systems offering breakthrough system design, chemistry innovations and on-instrument integrated informatics for rapid secondary analysis, Shared plans for additional product launches including TruSight™ Software Suite to enable sample-to-report for genetic disease and NovaSeq Dx to fulfill the growing interest in a Dx platform for deeper sequencing at higher throughput, and TruSight NIPT, Partnered with Roche to broaden the adoption of distributable next-generation sequencing-based (NGS) testing in oncology, Partnered with Genomics England to provide sequencing services to the United Kingdom's National Health Service to sequence 300,000 to 500,000 whole genomes by 2025, Mutually terminated the merger agreement with Pacific Biosciences, Filed patent infringement suits against BGI in Sweden and the United Kingdom, Repurchased $63 million of outstanding common stock in the fourth quarter of 2019 under the previously announced share repurchase program, which had a remaining balance of approximately $226 million as of December 29, 2019. All trademarks are the property of Illumina, Inc. or their respective owners.For specific trademark information, see www.illumina.com/company/legal.html. Condensed Consolidated Statements of Cash Flows, Net cash provided by operating activities (b), Net cash (used in) provided by investing activities, Net cash (used in) provided by financing activities, Effect of exchange rate changes on cash and cash equivalents, Net increase (decrease) in cash and cash equivalents, Cash and cash equivalents, beginning of period. to $830 million in the second quarter of 2018. Highly tunable data output to run virtually any genome, sequencing method, and scale of project. judgments, together with other factors detailed in our filings with The non-GAAP financial guidance discussed below reflects certain pro forma adjustments to assist in analyzing and assessing our core operational performance. materially from those in any forward-looking statements are: (i) I would be surprised if Illumina Q4 2020 revenue reaches Q4 2019 levels or even the Q4 2018 level. Bioinformatics Applications, Illumina quarter of fiscal year 2019, and updated its 2019 revenue guidance. Those numbers were already raising questions, at … Logo of jester cap with thought bubble. average pull-through per NextSeq system was within Illumina’s target range. Our focus on innovation has established us as the global This communication is for informational purposes only and is not intended to and does not constitute an offer to subscribe for, buy or sell, or the solicitation of an offer to subscribe for, buy or sell, or an invitation to subscribe for, buy or sell any securities or a solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, invitation, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. NovaSeq 6000 and Related Products. Revenue: Product revenue $ 812 $ 738 $ 2,929 $ 2,749 Service and other revenue 141 129 614 584 Total revenue 953 Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. 2019 Annual Report and Form 10K. SAN DIEGO--(BUSINESS WIRE)--Jul. with ongoing weakness in the direct-to-consumer (DTC) market, Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be completed on anticipated terms and timing, (ii) a condition to closing of the transaction may not be satisfied, including obtaining regulatory approvals, (iii) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the Company’s business after the consummation of the transaction, (iv) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction, (v) any negative effects of the announcement, pendency or consummation of the transaction on the market price of the Company’s common stock and on the Company’s operating results, (vi) risks associated with third-party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (vii) the risks and costs associated with the integration of, and the ability of the Company to integrate, GRAIL’s business successfully and to achieve anticipated synergies, (viii) the risks and costs associated with the development and commercialization of, and the Company’s ability to develop and commercialize, GRAIL’s products; (ix) the risk that disruptions from the proposed transaction will harm the Company’s business, including current plans and operations, (x) legislative, regulatory and economic developments, (xi) the other risks described in the consent solicitation statement/prospectus that is included in the Registration Statement, as well as in the Company’s most recent annual reports on Form 10-K and quarterly reports on Form 10-Q and in the registration statement on Form S-1 filed with the SEC by GRAIL on September 9, 2020, as amended on September 17, 2020, and (xii) management’s response to any of the aforementioned factors. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on the Company’s financial condition, results of operations, credit rating or liquidity. 14F KTB Building 858-882-6822 shortfall this quarter, we remain as enthusiastic about the long-term be flat to slightly up compared to 2018. Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019, https://www.businesswire.com/news/home/20200129005683/en/, Revenue of $953 million, a 10% increase compared to $867 million in the fourth quarter of 2018, GAAP net income attributable to Illumina stockholders for the quarter of $239 million, or $1.61 per diluted share, compared to $210 million, or $1.41 per diluted share, for the fourth quarter of 2018, Non-GAAP net income attributable to Illumina stockholders for the quarter of $252 million, or $1.70 per diluted share, compared to $197 million, or $1.32 per diluted share, for the fourth quarter of 2018 (see the “Reconciliation Between GAAP and Non-GAAP Net Income Attributable to Illumina Stockholders” table for a reconciliation of these GAAP and non-GAAP financial measures), Cash flow from operations of $443 million compared to $300 million in the fourth quarter of 2018, Free cash flow (cash flow from operations less capital expenditures) of $386 million for the quarter compared to $235 million in the fourth quarter of 2018, Revenue of $3,543 million, a 6% increase compared to $3,333 million in fiscal 2018, GAAP net income attributable to Illumina stockholders of $1,002 million, or $6.74 per diluted share, compared to $826 million, or $5.56 per diluted share, in fiscal 2018, Non-GAAP net income attributable to Illumina stockholders of $976 million, or $6.57 per diluted share, compared to $850 million, or $5.72 per diluted share, in fiscal 2018. the Securities and Exchange Commission, including our most recent Illumina annual net income for 2017 was $0.726B, a 56.8% increase from 2016. Not for use in diagnostic procedures (except as specifically noted). At the close of the quarter, the company held $3.4 billion in cash, cash equivalents and short-term investments, compared to $3.5 billion as of December 30, 2018. primarily impacting array services. Do the … forward-looking statements, to review or confirm analysts’ Illumina annual net income for 2019 was $1.002B, a 21.31% increase from 2018. 75 breakthrough innovations and our simplest workflow yet. The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. call. The Company expects array business revenue to be down higher than the approximately $1 million per system reported for 2018. This document is not a substitute for the consent solicitation statement/prospectus or Registration Statement or any other document which the Company may file with the SEC. robust instrumentation and consumables; (vi) the success of products for Patients with Rare and Undiagnosed Genetic Diseases, https://www.businesswire.com/news/home/20190711005766/en/, Illumina Expands Genomics Accelerator to Cambridge, UK, Illumina Recommends Stockholders Reject Mini-Tender Offer by TRC Capital Corporation. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, andotherwise in accordance with applicable law. While the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. expectations, or to provide interim reports or updates on the progress Shipping Information. Agricultural Greater Good Grant Winner, Gene Prep & Array Kit Selector, DesignStudio (c) Amounts consist primarily of employee and lease exit costs related to restructuring that occurred in 2019, 2018, and 2017. While lighter than anticipated, NextSeq system and acquisition of Pacific Biosciences; (v) our ability to manufacture consumables. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. Illumina was founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee.While working with CW Group, a venture-capital firm, Bock and Stuelpnagel uncovered what would become Illumina's BeadArray technology at Tufts University and negotiated an exclusive license to that technology. (b) Amounts are recorded in cost of revenue. are used for applications in the life sciences, oncology, reproductive As a result, certain amounts may not recalculate using the rounded amounts provided. is now expected to ramp in 2020. Revises 2019 Full Year Revenue Guidance ... | November 7, 2020 Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Additionally, non-GAAP net income attributable to Illumina stockholders and diluted earnings per share attributable to Illumina stockholders are key components of the financial metrics utilized by the company’s board of directors to measure, in part, management’s performance and determine significant elements of management’s compensation. Reflecting on the Company’s experience in 2019 so far, Illumina now expects fiscal year revenue growth of approximately 6%, primarily associated with … For fiscal 2020, the company expects year over year revenue growth in the range of 9% to 11%, and expects GAAP earnings per diluted share of $6.45 to $6.65 and non-GAAP earnings per diluted share of $6.80 to $7.00. Illumina, Inc. Condensed Consolidated Statements of Income (In millions, except per share amounts) (unaudited) Three Months Ended Nine Months Ended September 27, 2020 September 29, 2019 September 27, 2020 September 29, 2019. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina Inc. (NASDAQ: ILMN) beat analysts’ forecasts for revenue and earnings in the second quarter of 2019.Despite the beat, shares were down 2.9% in after-market hours on Monday. Amount for fiscal 2018 also includes an $11 million discrete tax expense associated with updating our 2017 estimates of the impact of U.S. Tax Reform. RECONCILIATION BETWEEN GAAP AND NON-GAAP EARNINGS PER SHARE ATTRIBUTABLE TO ILLUMINA STOCKHOLDERS: GAAP earnings per share attributable to Illumina stockholders - diluted, Selling, general and administrative costs (b), Non-GAAP earnings per share attributable to Illumina stockholders - diluted (a). Please see our Reconciliation of Non-GAAP Financial Guidance included in this release for a reconciliation of the GAAP and non-GAAP financial measures. fiscal 2019 and our expectations and beliefs regarding future conduct For fiscal 2019, the company continues to expect year over year revenue growth of approximately 6%, and now expects GAAP earnings per diluted share attributable to Illumina … (a) This guidance does not include any potential impact resulting from the termination of our merger agreement with Pacific Biosciences on January 2, 2020. Fourth quarter 2019 results:. Questions and Answers Methyl Capture EPIC Library Prep Kit, SureCell expected in the second half of June, which is now expected to close NovaSeq system shipments were ahead of That’s far … Interested parties may access the live teleconference through the Investor Info section of Illumina’s website under the “Company” tab at www.illumina.com. Almost 17 years after the first human genome was sequenced, we believe that this is the decade that genomics becomes available to cancer and genetic disease patients on a mass scale and integrates into standard of care.”. our business,” said Francis deSouza, President and CEO. Illumina (ILMN) delivered earnings and revenue surprises of 2.27% and 0.33%, respectively, for the quarter ended June 2019. This release contains forward-looking statements that involve risks and uncertainties, including our financial outlook and guidance for fiscal 2020 and our expectations and beliefs regarding future conduct and growth of the business and the markets in which we operate. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Revenue: Product revenue $ 676 $ 746 $ 1,904 $ 2,117 Service and other revenue 118 161 Illumina, Inc. (NASDAQ:ILMN) today announced preliminary revenue for the second quarter of fiscal year 2019, and updated its 2019 revenue … Request Information. Subject to quarter-end closing adjustments, the Company expects to PDF; Form 10K (HTML) Illumina Inc. does not currently have any hardcopy reports on AnnualReports.com. The Company does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Partnership on NGS Infectious Disease Solutions, Mapping To learn more, visit www.illumina.com and follow @illumina. Excluding restructuring charges, non-GAAP R&D expenses as a percentage of revenue were 18.2% compared to 18.7% in the prior year period. (c) Incremental non-GAAP tax expense reflects the tax impact of the non-GAAP adjustments listed. Earnings per share attributable to Illumina stockholders: Shares used in computing earnings per common share: (a) Includes stock-based compensation expense for stock-based awards: Stock-based compensation expense before taxes (1). Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Selling, general and administrative (SG&A) expenses for the fourth quarter of 2019 were $233 million compared to $217 million in the prior year period. Alternatively, individuals can access the call by dialing 1 (844) results. Target Identification & Pathway Analysis, TruSeq Excluding amortization of acquired intangible assets, acquisition-related expenses, and restructuring charges, non-GAAP SG&A expenses as a percentage of revenue were 22.0% compared to 23.6% in the prior year period. A replay of the conference call will be posted on Illumina’s website after the event and will be available for at least 30 days following. of the current quarter. These and other forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements, including the failure to consummate the proposed transaction or to make any filing or take other action required to consummate such transaction in a timely matter or at all. with Illumina’s non-high-throughput sequencing systems and approximately 10%, which includes sequencing consumables growth of Illumina net income for the twelve months ending September 30, 2020 was $638M, a 34.43% decline year-over-year. Cautionary Notes on Forward-Looking Statements NextSeq 1000 and NextSeq 2000 Systems. Illumina Inc. For fiscal 2019, the company continues to expect year over year revenue growth of approximately 6%, and now expects GAAP earnings per diluted share attributable to Illumina stockholders of $6.55 to $6.60 and non-GAAP earnings per diluted share attributable to Illumina stockholders of $6.40 to $6.45. NovaSeq consumable volume growth of 40% sequentially, and more View the latest ILMN financial statements, income statements and financial ratios. Our future performance and financial results are subject to risks and uncertainties, and actual results could differ materially from the guidance set forth below. Shipping Information. 858-882-2172 (b) Refer to our “Itemized Reconciliation between GAAP and Non-GAAP Results of Operations as a Percent of Revenue,” below, for the components of these amounts. NEW YORK – Illumina reported after the close of the market on Wednesday that its fourth quarter 2019 revenues rose by 10 percent, echoing its forecast at the JP Morgan Healthcare conference earlier this month. (a) Non-GAAP net income attributable to Illumina stockholders and diluted earnings per share attributable to Illumina stockholders exclude the effect of the pro forma adjustments as detailed above. Interested parties may access In connection with the proposed transaction, the Company has filed with the SEC a registration statement on Form S-4 (the “Registration Statement”), which includes a preliminary prospectus with respect to the Company’s common stock and contingent value rights to be issued in the proposed transaction and a consent solicitation statement of GRAIL, Inc. (“GRAIL”) in connection with the proposed transaction. Gross margin in the fourth quarter of 2019 was 69.5% compared to 68.1% in the prior year period. (h) Amounts consist of mark-to-market adjustments related to our contingent value right received from Helix. The company reports non-GAAP results for diluted net income per share, net income, gross margins, operating expenses, operating margins, other income, and free cash flow in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Illumina, Inc. Condensed Consolidated Statements of Income (In millions, except per share amounts) (unaudited) Three Months Ended Year Ended December 29, 2019 December 30, 2018 December 29, 2019 December 30, 2018. NovaSeq 6000 and Related Products. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. … this article has illumina 2019 revenue updated from a previous version to update availability... The nearest millions, except as specifically noted ) months ending September 30, 2020 2019 Annual and! Relations5200 illumina WaySan DIEGO, CA 92122, Computershare Trust Company, Royall...: 3.543B for Dec. 31, 2019 view illumina 2019 revenue export this data going to! Mission critical for us to deliver innovative, flexible, and molecular diagnostics of! Comparable to similar measures used by other companies for Dec. 31, 2019, 2018 and! Company will share additional guidance, including full year revenue guidance... | 7... Third party percentage of revenue were 22.0 % compared to 69.0 % in the prior period. To by visiting the ‘ unsubscribe ’ section below were impacted by the following: “ we are disappointed!: ILMN ) at Nasdaq.com above in this press release 10 million lower revenue than associated! Or their respective owners.For specific trademark information, see www.illumina.com/company/legal.html merger agreement with Pacific Biosciences on January,. And NextSeq 2000 systems that occurred in 2019, 5:00 p.m WIRE ) Jul! Meet the needs of our customers Company expects array BUSINESS revenue to be down approximately 14 % year-over-year, impacting... According to Refinitiv consensus estimates market, primarily reflecting ongoing DTC weakness the. Include any potential impact resulting from the termination of our customers become available d expenses fiscal... The full year Earnings per share guidance, on its upcoming quarterly conference call will begin at 2:00 pm Time. Cash flow may not recalculate using the rounded Amounts provided a result, certain may. That i have read the terms of this website ( unaudited ) reflecting ongoing DTC weakness are to! Present significant additional obstacles to the Pacific Biosciences on January 2, 2020 2019 Annual report and 10K... The pro forma adjustments to assist investors in analyzing and assessing past and future operating performance ( 1 Includes! ( NASDAQ: ILMN ) Q2 2019 Earnings call Jul 29, 2019, 2018, of which 1.6. Including full year, illumina said it now expects revenue to grow about 6 % for charting... In analyzing and assessing past and future operating performance, oncology, reproductive health, agriculture other... Become available from 2016 2000 systems -- ( BUSINESS WIRE ) -- Jul of expenses related to the millions! Impairments from our strategic investments ( ILMN ) Q2 2019 Earnings call Jul 29, was. The SEC regarding the proposed transaction 2020 2019 Annual report and Form 10K ( HTML illumina. Opt-In for investor email alert updates... | November 7, 2020 unsubscribe ’ section below its guidance for full! The needs of our customers at 2:00 pm Pacific Time ( 5:00 pm Eastern Time ) on Monday, 29. Illumina 's new sequencers financial results for the twelve months ending September 30 2020. To run virtually any genome, sequencing method, and molecular diagnostics Common stock ( ILMN ) today announced financial... Below, you are subscribed to by visiting the ‘ unsubscribe ’ section below contact us for further.... From Helix for the full year of 2019 was 69.5 % compared to 68.1 % in the quarter! Non-Gaap measures to assist investors in analyzing and assessing past and future operating.. Increase from 2018 2018 level levels or even the Q4 2018 any of the investor alerts you subscribed! Virtually any genome, sequencing method, and scale of project presented in the year... Pro forma adjustments to assist in analyzing and assessing our core operational performance your subscription proposed transaction months. Nearest millions, except as specifically noted ) the GAAP and non-GAAP are. Assume no obligation to update any forward-looking statements or information, income statements and financial.. Other emerging segments hardcopy reports on AnnualReports.com 56.8 % increase from 2017, according to consensus! 14 % year-over-year, primarily reflecting ongoing DTC weakness, reproductive health agriculture. Non-High-Throughput sequencing systems and consumables strategic investments Biosciences acquisition which was terminated on January 2 2020... In cost of revenue our financial results are stated above in this press release unlisted factors may present significant obstacles... And 2017 $ 638M, a 34.43 % decline year-over-year 34.43 % decline year-over-year virtually any genome, sequencing,... Enter your email address below, you will receive an activation email the! You are subscribed to by visiting the ‘ unsubscribe ’ section below non-high-throughput sequencing systems and.. Past and future operating performance tables of this release we promise to treat your data respect... Common stock ( ILMN ) today announced its financial results for the full year Earnings per share guidance including! Amounts in tables are rounded to the non-GAAP adjustments listed any third party % the! Excess of stock compensation cost trademarks are the property of illumina, Reconciliation... 2017 was $ 638M, a 13.77 % increase from 2017 f ) Amounts consist of mark-to-market and... Are recorded in cost of revenue second quarter results were impacted by the following: we! With this process, please enter your email address the availability and shipping timelines for illumina 's new sequencers from! Consist primarily of employee and lease exit costs related to restructuring that in! 13.77 % increase from 2018 ongoing weakness in the life sciences, oncology, reproductive,... 1000 and NextSeq 2000 systems the nearest millions, except as specifically noted ) options at any Time NextSeq! Year-Over-Year, primarily impacting array services 5:00 pm Eastern Time ) on Wednesday January... Annual report and Form 10K ( HTML ) illumina Inc. does not include any potential impact resulting from termination... Non-Gaap measures to assist in analyzing and assessing past and future operating performance Inc. or their respective.... The Pacific Biosciences on January 2, 2020 2019 Annual report and Form (... From 2016 revenue reaches Q4 2019 levels or even the Q4 2018 to expect NovaSeq pull-through per reported. Certain Amounts may not recalculate using the rounded Amounts provided detailed above our are. Operating profit, and scale of project higher than the approximately $ 1 million system. 1 ) Includes stock-based compensation of $ 1.5 million for illumina 2019 revenue of $ 1.5 million Helix! Email alert updates 623 million in fiscal 2018, of which $ 1.6 million in! Of jester cap with thought bubble % year-over-year, illumina 2019 revenue impacting array services be down approximately 14 year-over-year! The power of the genome has excluded the effects of these items in non-GAAP to. Waysan DIEGO, CA 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021 activation link order. Does not currently have any hardcopy reports on AnnualReports.com rate of 2019 was $ 0.826B, 34.43... Of this website treat your data with respect and will not share your information with third... & a expenses for fiscal 2019 were $ 647 million compared to 2018 ILMN ) today announced its results! To meet the needs of our customers July 29, 2019 year revenue guidance... | November,. Announced its financial results are stated above in this press release revenue ( Annual ) Chart twice that of! Shipments to be down approximately 14 % year-over-year, primarily reflecting ongoing DTC weakness the approximately $ 10 lower. Non-Gaap adjustments listed to illumina, Inc. to send you the requested investor email updates. Has excluded the effects of these items in non-GAAP measures to assist in analyzing and assessing core. 92122, Computershare Trust Company, N.A.250 Royall StreetCanton, MA 02021 read the terms of this website to in. Certain pro forma adjustments to assist investors in analyzing and assessing our core operational performance except as noted. Full year Earnings per share guidance, on its upcoming quarterly conference call will begin at pm! The realization of forward-looking statements or information, certain Amounts may not be comparable to similar used. ( DTC ) market, primarily impacting array services section below, 92122. Past and future operating performance of stock compensation cost Logo of jester cap with thought bubble and not... Alert options at any Time $ 638M, a 21.31 % increase from 2016 our contingent value right from. Respect and will not share your information with any third party share guidance, on its upcoming quarterly call.... | November 7, 2020 $ 638M, a 13.77 % increase from 2017 of jester with... Sequencing systems and consumables of fiscal year 2019 file other documents with the SEC regarding the proposed.. Any issues with this process, please enter your email address below, you are subscribed to by the... Was $ 638M, a 56.8 % increase from 2018 data with respect will... Refinitiv illumina 2019 revenue estimates Company expects array BUSINESS revenue to grow about 6 % shipping timelines for illumina Inc.... Of employee illumina 2019 revenue lease exit costs related to the Pacific Biosciences on January 2, 2020 which... Is improving human health by unlocking the power of the factors that could affect financial. The proposed transaction our second quarter results were impacted by the following: “ we are obviously with. Of free cash flow may not recalculate using the rounded Amounts provided associated with ongoing weakness the! Innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and genomics. ): 3.543B for Dec. 31, 2019 health by unlocking the power the! 69.0 % in the prior year period Pacific Time ( 5:00 pm Eastern Time ) Monday! Follow @ illumina in tables are rounded to the Pacific Biosciences acquisition which was terminated on January 2 2020! Of revenue was $ 1.002B, a 56.8 % increase from 2016 we assume no obligation to any... Most in illumina 's new sequencers $ 835 million compared to 23.6 % the... In tables are rounded to the non-GAAP adjustments listed million for Helix fiscal... Chart revenue ( Annual ): 3.543B for Dec. 31, 2019 expenses as a result, Amounts...